Health & Biotech
Neurotech International Limited (ASX:NTI) is a clinical-stage biopharmaceutical development company focused predominately on paediatric neurological disorders, where there is persistent neuroinflammation. Neurotech has completed a Phase I/II clinical trial in Autism Spectrum Disorder (ASD), which demonstrated excellent safety and efficacy results at 28 days, 20 weeks and 52 weeks of treatment with NTI164. The Company commenced Phase II/III randomised, double-blind, placebo controlled clinical trial in ASD in Q4 CY2022. Neurotech is also conducting additional Phase I/II trials in Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) and Paediatric Acute-Onset Neuropsychiatric Syndrome (PANS), collectively PANDAS/PANS, along with Rett Syndrome and Cerebral Palsy during CY2023.
NTI164 is a proprietary drug formulation derived from a unique cannabis strain with low THC (M<0.3%) and a novel combination of cannabinoids including CBDA, CBC, CBDP, CBDB and CBN.
NTI164 has been exclusively licenced for neurological applications globally. Pre-clinical studies have demonstrated a potent anti-proliferative, anti-oxidative, anti-inflammatory and neuro-protective effects in human neuronal and microglial cells. NTI164 is being developed as a therapeutic drug product for a range of neurological disorders in children where neuroinflammation is involved.
KEY PEOPLE
RELATED STOCKHEAD STORIES
Health & Biotech
Check up: A good fortnight to be a small cap health investor
Health & Biotech
Check up: Sometimes no news is good news
Health & Biotech
Bondi backpackers rejoice! Recce may have a gonorrhoea cure
News
Rise and Shine: What you need to know before the ASX opens
Health & Biotech
WA biotechs are booming; now government wants to make the state a life sciences hub
News
Trading Places: Here are this week’s substantial holder movements
News
Weekly ASX small cap wrap: Who got themselves ready for the Superbowl this week?
Health & Biotech
Health: Antisense’s anti-muscular dystrophy drug just took a big step
News
10 ASX small caps that doubled (and tripled!) in a single day in 2019
News
Rise and Shine: What you need to know before the ASX opens
Health & Biotech
Health: G Medical is close to listing on the NASDAQ and Hong Kong exchanges
News
Rise and Shine: What you need to know before the ASX opens
News
Weekly ASX small cap wrap: who’s knocking off early this week?
News
Rise and Shine: What you need to know before the ASX opens
News
Lunchtime ASX small cap wrap: Who’s learning what it’s like to miss out today?
News
Rise and Shine: What you need to know before the ASX opens
News